Cover Image

Efficacy of CARVYKTI in CARTITUDE-4 versus other conventional treatment regimens for lenalidomide-refractory multiple myeloma using inverse probability of treatment weighting

Aim: The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexamethasone (PVd) for relapsed/refractory multiple myel...

Full description

Saved in:

Bibliographic Details
Main Authors:	Winfried Alsdorf (Author), Joris Diels (Author), Francesca Ghilotti (Author), Joao Mendes (Author), Teresa Hernando (Author), Patricia Cost (Author), Jordan M Schecter (Author), Nikoletta Lendvai (Author), Nitin Patel (Author), Ana Triguero (Author), Margherita Ursi (Author)
Format:	Book
Published:	Becaris Publishing Limited, 2024-08-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ameliorating the antitumor activity of lenalidomide using PLGA nanoparticles for the treatment of multiple myeloma
by: Veera Venkata Satyanarayana Reddy Karri, et al.
Published: (2017)

Exacerbation of psoriasis induced by lenalidomide in a patient with multiple myeloma
by: Guido Mioso, et al.
Published: (2023)

PHA RMA COE CONOMI CAL EVALUATION OF MULTIPLE MYELOMA TREATMENT WITH REVLIMID (LENALIDOMIDE ) IN THE RUSSIAN FEDE RATION
by: R. Yagudina, et al.
Published: (2015)

Disease biology alters the response to frontline bortezomib, lenalidomide and dexamethasone in Multiple Myeloma
by: Amany R Keruakous, et al.
Published: (2021)

Treatment-Associated Acute Lymphoblastic Leukemia Following Autologous Hematopoietic Stem Cell Transplant and Lenalidomide Maintenance in Patients With Multiple Myeloma
by: James Crosby DO, et al.
Published: (2022)

Clinical and economic implications of using daratumubab with lenalidomide in the 1st and 2nd lines of therapy for multiple myeloma patients
by: О. I. Ivakhnenko, et al.
Published: (2024)

Severe cutaneous scleromyxedema treated by lenalidomide
by: Théo Brochet, et al.
Published: (2023)

Lenalidomide as potential treatment in small cell neuroendocrine lung cancer with del 5q
by: Paul Hartel
Published: (2018)

An Overview of Lenalidomide in Combination with Rituximab for the Treatment of Adult Patients with Follicular Lymphoma: The Evidence to Date
by: Yilmaz U, et al.
Published: (2021)

A case of scleromyxedema responding to lenalidomide and dexamethasone
by: Sweta Rambhia, et al.
Published: (2017)

Improvement of primary vulvar Langerhans cell histiocytosis with lenalidomide
by: Steven Morrison, BA, et al.
Published: (2021)

ID200 Pharmaceutical Innovativeness Index (PII) como Estratégia de Precificação de Inovações Farmacêuticas: Estudo de Caso da Terapia Carvykti®
by: Ludmila Peres Gargano, et al.
Published: (2024)

Outcome of Lenalidomide Treatment for Cognitive Impairment Caused by Immune Reconstitution Inflammatory Syndrome in Patients with HIV-Related Cryptococcal Meningitis
by: Tao R, et al.
Published: (2022)

Clonorchis sinensis on the prognosis of patients with spontaneous rupture of Hepatocellular Carcinoma: An inverse probability of treatment weighting analysis.
by: Hang-Hang Ni, et al.
Published: (2024)

Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists
by: Calogero Pagliarello, et al.
Published: (2022)

In-hospital rehabilitation in the treatment of multiple myeloma
by: Alicja Mińko, et al.
Published: (2021)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011)

The place of thalidomide in the treatment of multiple myeloma
by: Alessandro Corso, et al.
Published: (2011)

A rare case report of photosensitivity in non-hodgkin's lymphoma treated with lenalidomide
by: Rajesh K Soni, et al.
Published: (2020)

Ixekizumab for the treatment of acrodermatitis continua of hallopeau and inverse psoriasis
by: Rui Yuan Xia, et al.
Published: (2023)

Inverse Psoriasis: From Diagnosis to Current Treatment Options
by: Micali G, et al.
Published: (2020)

Lenalidomide in cancer cachexia: a randomized trial of an anticancer drug applied for anti‐cachexia
by: David Blum, et al.
Published: (2022)

Pathogenesis and treatment of multiple myeloma bone disease
by: Masahiro Hiasa, et al.
Published: (2021)

Novel Experimental Drugs for Treatment of Multiple Myeloma
by: Offidani M, et al.
Published: (2021)

Spotlight on ixazomib: potential in the treatment of multiple myeloma
by: Muz B, et al.
Published: (2016)

Historical perspective and advances in the treatment of multiple myeloma
by: Amir Harandi, et al.
Published: (2011)

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma
by: Pan Zhou, et al.
Published: (2022)

Fertility-Sparing surgery for young women with ovarian endometrioid carcinoma: a multicenteric comparative study using inverse probability of treatment weighting
by: Hiroaki Kajiyama, et al.
Published: (2019)

Lenalidomide Augments Differentiation of Cultured Hair Follicle Derived Melanocyte Stem Cells Into Functional Melanocytes
by: Uma Kumari, et al.
Published: (2023)

Targeted treatments for multiple myeloma: specific role of carfilzomib
by: Sugumar D, et al.
Published: (2015)

Clinical Use of Proteasome Inhibitors in the Treatment of Multiple Myeloma
by: Noah M. Merin, et al.
Published: (2014)

The Role of Monoclonal Antibodies in the Treatment of Myeloma Kidney Disease
by: Daniele Derudas, et al.
Published: (2024)

Monocytosis and Multiple Myeloma: treatment-related acute leukaemia?
by: Cristina Veronica Trinidad Esparza, et al.
Published: (2022)

Nanoparticles Dual Targeting Both Myeloma Cells and Cancer-Associated Fibroblasts Simultaneously to Improve Multiple Myeloma Treatment
by: Honglan Wang, et al.
Published: (2021)

Pityriasis lichenoides chronica in a patient on tafasitamab and lenalidomide therapy for diffuse large B-cell lymphoma
by: Katie Roster, MS, et al.
Published: (2023)

Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship
by: Zaiwei Song, et al.
Published: (2022)

Development and Validation of an Improved HPLC-MS/MS Method for Quantifying Total and Unbound Lenalidomide in Human Plasma
by: Suhyun Lee, et al.
Published: (2024)

SOME ASPECTS OF EPIDEMIOLOGY, PATHOGENESIS, DIAGNOSIS AND TREATMENT OF MULTIPLE MYELOMA
by: S.N. ABDULLAEVA
Published: (2021)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
by: Alessandro Gozzetti, et al.
Published: (2022)

Pomalidomide in the treatment of multiple myeloma: design, development and place in therapy
by: Rios-Tamayo R, et al.
Published: (2017)